An international study involving researchers from UBC Okanagan has shown that MDMA, also known as ecstasy, may be a valuable tool for treating post-traumatic stress disorder (PTSD).
Published recently in Psychopharmacology, the study demonstrated substantial improvements in individuals who had not responded to prior treatments, explains UBCO Associate Professor of Psychology Zach Walsh. This is also, he adds, the most comprehensive evaluation of the safety and effectiveness of MDMA-assisted psychotherapy for PTSD.
“PTSD symptoms decreased after one session of MDMA together with psychotherapy,” says Walsh, study co-author. He adds that 54 per cent of participants no longer met PTSD criteria after two sessions and that there was also improvement in their symptoms of depression.
The response of participants to MDMA-assisted psychotherapy was compared to those who received small doses or non-drug psychotherapy.
“These findings are promising and indicate the needed for larger studies,” says Walsh. “Too many people with PTSD struggle to find effective treatment, and use of MDMA in a supportive environment with trained mental health professionals could be an important addition to our treatment options.”
Ecstasy, also known as Molly, is the nickname for MDMA—a synthetic drug made from a combination of methylenedioxy-methamphetamine. It is a controlled, illegal drug in Canada classified as a stimulant with hallucinogenic properties.
Walsh, as well as researchers from the United States, Switzerland and Israel, examined the results from six clinical trials, involving 103 people. Trial participants included men and women with chronic, treatment-resistant PTSD from a wide variety of causes.
Based on these results, the US Food and Drug Administration granted breakthrough therapy designation to MDMA-assisted psychotherapy for PTSD, acknowledging that it “may demonstrate substantial improvement over existing therapies” and agreeing to expedite its development and review.
The first of two more in-depth clinical trials of MDMA-assisted psychotherapy for PTSD began enrolling participants in November 2018 and aims to have 100-150 volunteers across 15 sites in the US, Canada, and Israel. The second trial will take place after an interim analysis of the data from the first trial, and will enrol an additional 100-150 participants. European trials are planned to start in the near future.
Nearly four per cent of all people worldwide will suffer from PTSD during their lifetime. PTSD can be a debilitating disorder, with symptoms including intrusive thoughts and memories, negative effects on thinking and mood, depression, hyperarousal and reactivity, and avoidance. People with PTSD can experience much lower quality of life and relationships, related mental health conditions and suicidal tendencies.
The Latest on: PTSD treatment
via Google News
The Latest on: PTSD treatment
- The potential role of the HCN1 ion channel and BDNF-mTOR signaling pathways and synaptic transmission in the alleviation of PTSDon March 20, 2020 at 9:36 am
The function of the hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) and the expression of brain-derived neurotrophic factor (BDNF) may be involved in the pathogenesis of ...
- PTSD, TBI, or Both?on March 20, 2020 at 9:10 am
weaves back to the diagnoses of " shell shock " during World War I, and even earlier to the Napoleonic Wars and the American Civil War. Dr. Charles Samuel Myers, a consulting psychologist and ...
- PTSD strongly linked with heart disease in female veteranson March 18, 2020 at 5:22 am
Further research could also shed light on whether the relationship between PTSD and heart disease also extends to women who have not served in the armed forces. ACC.20/WCC will take place March 28-30, ...
- Local doctor is leading the way in the comprehensive treatment of migraineon March 17, 2020 at 2:45 pm
Metro caught up with Patrick Sullivan, D.O., who works in a neurologic emergency department and is the founder and medical director of Initia Nova—one of New Jersey's leading treatment centers that ...
- 'Psyched': First Psychedelics Company Lists Publicly, Phase III Clinical Trials On MDMA For PTSDon March 16, 2020 at 12:10 am
Israel Completed Phase III Clinical Trials on MDMA for PTSD Two Israeli participants were the first to complete a Phase III clinical study using MDMA as a treatment for Post-Traumatic Stress Disorder, ...
- 'Psyched': First Psychedelics Company Goes Public, Phase III Clinical Trials On MDMA For PTSDon March 15, 2020 at 2:38 am
Two Israeli participants were the first to complete a Phase III clinical study using MDMA as a treatment for Post-Traumatic Stress Disorder, announced the Multidisciplinary Association for Psychedelic ...
- PTSD and Anger: Untangling the Connectionon March 13, 2020 at 6:02 am
When a person presents with a secondary condition, such as depression or IED, their PTSD may go unnoticed and untreated. This prolongs their suffering and may cause them to drop out of treatment, ...
- Is PTSD a Double-Edged Sword?on March 12, 2020 at 1:08 pm
Posttraumatic stress disorder or PTSD has evolved into a seemingly common diagnosis for service members and veterans, and it’s been widely publicized by the media. The positive side of this publicity ...
- Poway High grad walking across country hopes to get people talking about PTSDon March 11, 2020 at 1:37 pm
A Poway High graduate is hoping to get people talking about PTSD by walking over 6,000 miles across America. Stephen Meyers, who graduated from Poway High in 1994 and served 22 years in the military, ...
- Veterans 'Catch A Lift' and battle PTSD at the same timeon March 11, 2020 at 12:47 am
"Physical exertion is some of the best treatment for PTSD I've ever found," he said. "It's like my nirvana, to be honest with you." And Marine veteran Jose Ivan Perez from Austin, who had his hand ...
via Bing News